EIM
KNSA icon

Essex Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Essex Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Sell
241,382
-7,896
-3% -$410K 2.02% 3
2026
Q1 		$12M Sell
249,278
-1,697
-0.7% -$75.2K 1.9% 4
2025
Q4 		$10.4M Buy
250,975
+3,674
+1% +$147K 1.58% 7
2025
Q3 		$9.6M Buy
247,301
+75,864
+44% +$2.46M 1.47% 9
2025
Q2 		$4.74M Sell
171,437
-1,229
-0.7% -$31.3K 0.86% 30
2025
Q1 		$3.83M Sell
172,666
-1,133
-0.7% -$23.3K 0.8% 37
2024
Q4 		$3.44M Sell
173,799
-26,717
-13% -$610K 0.62% 56
2024
Q3 		$5.01M Buy
200,516
+717
+0.4% +$17.5K 0.87% 33
2024
Q2 		$3.73M Buy
199,799
+27,059
+16% +$507K 0.7% 46
2024
Q1 		$3.41M Buy
172,740
+850
+0.5% +$16.6K 0.67% 49
2023
Q4 		$3.01M Sell
171,890
-13,963
-8% -$229K 0.59% 52
2023
Q3 		$3.23M Sell
185,853
-2,445
-1% -$41.2K 0.53% 59
2023
Q2 		$2.65M Buy
188,298
+69,128
+58% +$925K 0.37% 96
2023
Q1 		$1.28M Buy
+119,170
New +$1.57M 0.19% 167

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Essex Investment Management's KNSA Position: Q2 2026 in Review

Essex Investment Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 3.2% in Q2 2026, selling an estimated $410K and leaving 241,382 shares worth $15.4M. The position accounts for 2.02% of the portfolio, ranked #3.

Essex Investment Management first reported a position in KNSA in Q1 2023 and has held it in 14 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Essex Investment Management held 241,382 shares of Kiniksa Pharmaceuticals worth $15.4M as of Q2 2026.
  • Essex Investment Management sold 7,896 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $410K.
  • Kiniksa Pharmaceuticals made up 2.02% of Essex Investment Management's portfolio in Q2 2026, its #3 holding.
  • Essex Investment Management first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Essex Investment Management's 13F filing for Q2 2026, filed 6 Aug 2026.